acr do not miss - emeunet 2016 dnm issue_final.pdfacr do not miss acr 2016 washington oral...

EDITION OCTOBER 2016

ACR DO NOT MISS

ACR 2016 WASHINGTON

Oral presentations and posters

Mentor/Mentee meetings

Networking event

EDUCATIONAL EVENTS

WORLD ARTHRITIS DAY

Hilfslinien anzeigen über Menu:

Ursprungsform

im Menü über:

Start | Absatz | Listenebene

DIRECTORY

EDITORIAL

PAGE 2

Dear young rheumatologistsand researchers inrheumatology,

We are happy to present you a new issue

of EMEUNEWS about the Do-Not-Miss

Topics of this year´s ACR annual

meeting.

The ACR congress is one of the largest

scientific event in Rheumatology. As it is

now approaching, we provide a selection

of oral presentations and posters that we

consider to be noteworthy. Albeit this is a

limited way of looking at the numerous

scientific releases at ACR 2016, it might

provide an overview of hot topics in each

field of Rheumatology. From this issue

we also included the new topic “Rare and

autoinflammatory diseases”.

In addition, this Newsletter contains

details about EMEUNET events

organized during the Congress.

EMEUNET is now active in social media

hubs such as Facebook and Twitter,

while maintaining the traditional website

and the important physical (and

personal) presence at major

Rheumatology scientific events.

If this is your first contact with

EMEUNET, we invite you to explore

more and join us. If you are already part

of our community, we kindly remind you

that sharing is caring. Spread the word

about our activities and work, and help us

reach more young rheumatologists and

researchers.

We hope you enjoy reading this

Newsletter. We always welcome

feedback, comments, suggestions and

contributions.

We wish you a prolific and successful

ACR 2016

See you in Washington!

Richard Conway, Antonis Fanouriakis

and Alessia Alunno

on behalf of the Newsletter Subgroup

ACR 2016: ORAL PRESENTATIONS & POSTERS 4

Basic Research I

Basic Research II

RA I

RA II

RA III

Psoriatic Arthritis

Axial Spondyloarthritis

SLE and APS

Other connective tissue diseases

Imaging

Crystal Arthropathies

Osteoarthritis & Osteoporosis

Pediatric Rheumatology

Rare and Autoinflammatory Diseases

MENTOR MENTEE MEETINGS 17

EMEUNET NETWORKING EVENT 18

EDUCATIONAL EVENTS 19

WORLD ARTHRITIS DAY 2016 21

More information about EMEUNET can be found

in http://emeunet.eular.org

You can also reach us through the following

email [email protected]

www.facebook.com/EMEUNET

www.twitter.com/EMEUNET


Folie in Ursprungsform

Wechsel der Textebene/Formatierungen

Start

PAGE 3

Anne finished her medical degree at the University of Aarhus in 2007 and basic training in surgery and internal medicine in 2010, and then

began her specialist training in Rheumatology. She is currently doing a PhD in innate immunity and SLE. Her fields of interest include

immunology, the complement system, SLE and CTDs. Anne is the EMEUNET country liaison for Denmark.

BASIC RESEARCH I

Genetics, cartilage/synovium, osteoimmunology, animal models

Anne Troldborg

ORAL PRESENTATIONS & POSTERS ACR 2016 WASHINGTON

Type, n° Date, time Session Room Author Title

Poster

297

Sunday

13.11.2016

9.00-11.00

Osteoarthritis - Clinical

Aspects - Poster I

Poster Hall

Hall C

Yau M

(USA)

GENETIC AND ENVIRONMENTAL

CORRELATION OF OSTEOARTHRITIS AT

THE HANDS, KNEES, AND SPINE

Poster

581

Sunday

13.11.2016

9.00-11.00

Rheumatoid arthritis -

Human etiology and

Pathogenesis - Poster I

Poster Hall

Hall C

Gazitt T

(USA)

CELL-MEDIATED NEUTROPHIL LYSIS-A

MECHANISM PROMOTING

HYPERCITRULLINATION IN RHEUMATOID

ARTHRITIS?

Oral

918

Sunday

13.11.2016

15:15

B Cell Biology and

Targets in Autoimmune

Disease I

150 AManion K

(Canada)

ANERGIC B CELLS MAY PRESERVE

PERIPHERAL TOLERANCE IN LUPUS-

PRONE CONGENIC MICE

Poster

1917

Monday

14.11.2016

9.00-11.00

T Cell Biology and


Disease - Poster I

Poster Hall

-Hall C

Greisen S

(Denmark)

RHEUMATOID ARTHRITIS CELLS

PRODUCE EXTRACELLULAR VESICLES

THAT INCORPORATE PD-1 AND

MICRORNAS TARGETING THE PD-1

PATHWAY IN SURROUNDING CELLS

Oral

2068

Monday

14.11.2016

16:30

Systemic Sclerosis,

Fibrosing Syndromes

and Raynaud's –

Pathogenesis, Animal

Models and Genetics I

Ballroom BWeber S

(Germany)

TYPE 2 INNATE LYMPHOID CELLS –

CELLULAR SOURCE OF PROFIBROTIC

MEDIATORS RAPIDLY AND

PERSISTENTLY RECRUITED IN

EXPERIMENTAL FIBROSIS AND

SYSTEMIC SCLEROSIS

Oral

2036

Monday

14.11.2016

17:30

Genetics, Genomics

and Proteomics I147 A

Batu ED

(Turkey)

WHOLE EXOME SEQUENCING IN EARLY

ONSET SYSTEMIC LUPUS

ERYTHEMATOSUS

Oral

2998

Tuesday

15.11.2016

15:45

Biology and Pathology

of Bone and Joint150 A

Yan J

(USA)

GUT MICROBIOTA INDUCE IGF-1 AND

PROMOTE BONE FORMATION AND

GROWTH

Oral

3119

Wednesday

16.11.2016

09:00

Genetics, Genomics

and Proteomics II146 A

Rizi A

(USA)

COMPLETE WHOLE GENOME

TRANSCRIPTOME, DNA METHYLATION,

AND HISTONE MARK ANALYSIS OF

RHEUMATOID ARTHRITIS (RA)

FIBROBLAST-LIKE SYNOVIOCYTES (FLS)

REVEALS A DISTINCTIVE EPIGENETIC

LANDSCAPE AND CRITICAL

PATHOGENIC PATHWAYS




Start

PAGE 4

Javier is a postdoctoral researcher at the University of Oviedo (Spain). After completing a research stay at the Academic Medical Centre

(Amsterdam, The Netherlands), he obtained his PhD degree from the University of Oviedo in 2015. His main interests are the endothelial

damage and vascular repair in rheumatic diseases, with special focus on translational biomarkers for cardiovascular risk assessment.

BASIC RESEARCH II

Immunity, immunology

Javier Rodríguez-Carrio


Poster

185

Sunday

13.11.2016

09:00-11:00

Innate Immunity and

Rheumatic Disease -

Poster I

Poster Hall

Hall C

Cooles FAH

(UK)

THE INTERFERON GENE SIGNATURE

IS INCREASED IN EARLY DMARD

NAIVE RHEUMATOID ARTHRITIS AND

PREDICTS A POORER RESPONSE TO

INITIAL THERAPY

Oral

920

Sunday

13.11.2016

15:45

B Cell Biology and


Disease I

150 ARuff W

(USA)

AUTOANTIGEN-SPECIFIC T CELL AND

ANTIBODY REACTIVITY TO A HUMAN

GUT COMMENSAL IN

ANTIPHOSPHOLIPID SYNDROME

Oral

1009

Sunday

13.11.2016

17:30

Innate Immunity and

Rheumatic Disease146 A

Ah Kioon MD

(USA)

PLASMACYTOID DENDRITIC CELLS

ARE ACTIVATED IN SYSTEMIC

SCLEROSIS AND CONTRIBUTE TO

THE DISEASE BY INDUCING IFNΑ AND

CXCL4

Poster

2111

Tuesday

15.11.2016

09:00-11:00

B Cell Biology and


Disease - Poster II:

Rheumatoid Arthritis

and Other Rheumatic

Diseases

Poster Hall

Hall C

Germar K

(Netherlands)

GENERATION AND

CHARACTERIZATION OF ANTI-

CITRULLINATED PROTEIN ANTIBODY-

PRODUCING B-CELL CLONES

Poster

2255

Tuesday

15.11.2016

09:00-11:00

Innate Immunity and

Rheumatic Disease -

Poster II

Poster Hall

Hall C

Mistry P

(USA)

CHARACTERIZATION OF LOW-

DENSITY GRANULOCYTES IN

AUTOINFLAMMATORY DISORDERS

Poster

2264

Tuesday

15.11.2016

09:00-11:00

Innate Immunity and

Rheumatic Disease -

Poster II

Poster Hall

Hall C

De Jong A

(Netherlands)

LACK OF OBESITY-RELATED

CHANGES IN ADIPOCYTES AND

INFLAMMATORY CELLS IN THE

INFRAPATELLAR FAT PAD (IFP): A

DIFFERENT TYPE OF FAT?

Poster

2926

Tuesday

15.11.2016

09:00-11:00

B Cell Biology and


Disease - Poster II:


and Other Rheumatic

Diseases

Poster Hall

Hall C

Paulissen SMJ

(Netherlands)

RORC POSITIVE TH17, TH17/TH1, AND

TH17.1 CELLS FROM THE BLOOD OF

TREATMENT NAÏVE RA PATIENTS

DIFFER IN IL-17A BUT ARE ALL

PATHOGENIC WHEN CO-CULTURED

WITH RA SYNOVIAL FIBROBLASTS

Oral

3107

Tuesday

15.11.2016

16:30

T Cell Biology and


Disease - Oral Session

150 AYang Z

(USA)

SWITCHING FROM ANABOLIC TO

CATABOLIC METABOLISM – A NOVEL

IMMUNOMODULATORY THERAPY IN

RA





Start

PAGE 5

RA I

Epidemiology, clinics and non-biologics

Diederik De Cock


Poster

91

Sunday

13.11.2016

09.00

Health Services

Research -

Poster I

Poster Hall

Hall C

Grainger R

(New Zealand)

A SYSTEMATIC REVIEW OF

SMARTPHONE APPLICATIONS FOR

MEASURING AND RECORDING

RHEUMATOID ARTHRITIS DISEASE

ACTIVITY

Oral

951

Sunday

13.11.2016

14.30

Rheumatoid

Arthritis – Small

Molecules,

Biologics and

Gene Therapy

I: Treatment

Strategies

Hall EGlintborg B

(Denmark)

A NATIONWIDE NON-MEDICAL

SWITCH FROM ORIGINATOR TO

BIOSIMILAR INFLIXIMAB IN

PATIENTS WITH INFLAMMATORY

ARTHRITIS. ELEVEN MONTHS’

CLINICAL OUTCOMES FROM THE

DANBIO REGISTRY

Poster

1240

Monday

14.11.2016

09.00

Health Services

Research -

Poster II

Poster Hall

Hall C

Mars N

(Finland)

A MINORITY OF PATIENTS UTILIZE

MOST OF HEALTHCARE

RESOURCES IN RHEUMATOID

ARTHRITIS, PSORIATIC ARTHRITIS,

JUVENILE IDIOPATHIC ARTHRITIS,

AND AXIAL SPONDYLOARTHRITIS

Poster

1556

Monday

14.11.2016

09.00

Rheumatoid

Arthritis –

Clinical Aspects

- Poster II: Co-

morbidities and

Complications

Poster Hall

Hall C

Stouten V

(Belgium)

ASSESSMENT OF THE BURDEN OF

COMORBIDITIES BY THE

RHEUMATIC DISEASE

COMORBIDITY INDEX IN EARLY

RHEUMATOID ARTHRITIS PATIENTS

AT DISEASE ONSET

Oral

3024

Tuesday

15.11.2016

14.45

Rheumatoid

Arthritis – Small

Molecules,

Biologics and

Gene Therapy

III: Small

Molecules and

Early

Intervention

Ballroom CCharles-Schoeman C

(USA)

MAJOR ADVERSE

CARDIOVASCULAR EVENTS: RISK

FACTORS IN PATIENTS WITH RA

TREATED WITH TOFACITINIB

Oral

3069

Tuesday

15.11.2016

17.30

Epidemiology

and Public

Health II:

Obesity,

Cancer and

Mortality

146 ASparks JA

(USA)

WEIGHT LOSS IN THE EARLY

RHEUMATOID ARTHRITIS PERIOD

IS ASSOCIATED WITH

SUBSEQUENT INCREASED

MORTALITY IN RA PATIENTS AND

MATCHED COMPARATORS:

EVIDENCE AGAINST AN RA-

SPECIFIC OBESITY PARADOX

Diederik is a Belgian epidemiologist currently working in Manchester, UK. His PhD focused on the efficacy of different

intensive treatment strategies in early Rheumatoid Arthritis in the context of the Flemish CareRA trial. His post-doctoral work

focuses on safety of biological therapy in more established rheumatoid arthritis. His other areas of interest are steroid safety

and treatment delay. .





Start

PAGE 6

Richard has completed specialist training in rheumatology and general internal medicine and is currently a vasculitis fellow at

University College Dublin, Ireland. His major research interests include giant cell arteritis and meta-analysis. Richard is a

member of the EMEUNET Newsletter Subgroup.

RA II

Biological therapies: anti-TNF

Richard Conway


Poster

601

Sunday

13.11.2016

09.00


– Small Molecules,

Biologics and Gene

Therapy - Poster I

Poster Hall

Hall C

Dervieux T

(USA)

DIFFERING CONTRIBUTION OF

METHOTREXATE

POLYGLUTAMATION TO INFLIXIMAB

AND ADALIMUMAB EXPOSURE AS

COMPARED TO ETANERCEPT

Oral

2001

Monday

14.11.2016

15.45


– Small Molecules,

Biologics and Gene

Therapy II: Safety

and Cost

Effectiveness

Salon BJuo HH

(USA)

PERIOPERATIVE USE OF SYNTHETIC

DISEASE-MODIFYING ANTI-

RHEUMATIC DRUGS OR TUMOR

NECROSIS FACTOR Α INHIBITORS

DOES NOT ASSOCIATE WITH

INCREASED RATES OF POST-

OPERATIVE INFECTIONS

Oral

2052

Monday

14.11.2016

17.00


– Clinical Aspects III:

Prevention of

Comorbidity

Hall EGeorge MD

(USA)

PREOPERATIVE TIMING OF

INFLIXIMAB AND RISK OF POST-

OPERATIVE INFECTION IN A

MEDICARE COHORT

Poster

2482

Tuesday

15.11.2016

09.00


– Clinical Aspects -

Poster III: Treatment

– Monitoring,

Outcomes, Adverse

Events

Poster Hall

Hall C

Visman IA

(Netherlands)

LONG TERM DRUG SURVIVAL OF

ADALIMUMAB AND ETANERCEPT

TREATMENT FOR RHEUMATOID

ARTHRITIS WITH AND WITHOUT

METHOTREXATE

Oral

3011

Tuesday

15.11.2016

14.30


– Clinical Aspects IV:

Managing Patients in

Remission

Ballroom Bden Broeder AA

(Netherlands)

LONG-TERM OUTCOMES AFTER

DISEASE ACTIVITY GUIDED

TAPERING OF TUMOR NECROSIS

FACTOR INHIBITION IN RHEUMATOID

ARTHRITIS: 3 YEAR DATA OF A

RANDOMISED CONTROLLED

PRAGMATIC NON INFERIORITY

STRATEGY STUDY

Oral,

3012

Tuesday

15.11.2016

14.45


– Clinical Aspects IV:

Managing Patients in

Remission

Ballroom BMoghadam MG

(Netherlands)

CLINICAL PREDICTORS OF TNF-

INHIBITOR FREE DISEASE CONTROL

IN PATIENTS WITH RHEUMATOID

ARTHRITIS AFTER STOPPING TNFI

TREATMENT: RESULTS FROM A

DUTCH MULTICENTRE PRAGMATIC

OPEN-LABEL RANDOMIZED

CONTROLLED TRIAL.





Start

PAGE 7

Jan is a board-certified rheumatologist, has completed specialist training in Rheumatology and general internal medicine and

is currently an attending physician at University of Munich, Germany. His major research interests include early rheumatoid

arthritis and the role of T cells in the pathogenesis of autoimmune arthritis

RA III

Other biologics and new drugs beyond biologics

Jan Leipe


Oral

954

Sunday

13.11.2016

15.15

Rheumatoid

Arthritis – Small

Molecules,

Biologics and

Gene Therapy I:

Treatment

Strategies

Hall EBehrens F

(Germany)

EFFECTIVENESS OF DIFFERENT DOSAGES

OF RETREATMENT OF RITUXIMAB IN

COMBINATION WITH LEFLUNOMIDE:

RESULTS FROM A MULTICENTER

RANDOMIZED PLACEBO CONTROLLED

INVESTIGATOR INITIATED CLINICAL TRIAL

IN ACTIVE RA (AMARA-STUDY)

Poster

1591

Monday

14.11.2016

09.00

Rheumatoid

Arthritis-Small

Molecules,

Biologics and

Gene Therapy II

Poster Hall

Hall C

Taylor PC

(UK)

EFFICACY AND SAFETY OF SWITCHING

FROM ADALIMUMAB TO BARICITINIB:

PHASE 3 DATA IN PATIENTS WITH

RHEUMATOID ARTHRITIS

Poster

1616

Monday

14.11.2016

09.00

Rheumatoid

Arthritis-Small

Molecules,

Biologics and

Gene Therapy II

Poster Hall

Hall C

Burmester GR

(Germany)

MAVRILIMUMAB, A FULLY HUMAN

GRANULOCYTE-MACROPHAGE COLONY-

STIMULATING FACTOR RECEPTOR-Α

MONOCLONAL ANTIBODY: LONG-TERM

SAFETY AND EFFICACY FOR UP TO 158

WEEKS OF TREATMENT IN PATIENTS WITH

RA

Poster

1625

Monday

14.11.2016

09.00

Rheumatoid

Arthritis-Small

Molecules,

Biologics and

Gene Therapy II

Poster Hall

Hall C

Thorne C

(Canada)

ANALYSIS OF A PHASE 3 STUDY

EVALUATING THE EFFICACY OF

SIRUKUMAB, AN ANTI-IL-6 CYTOKINE

MONOCLONAL ANTIBODY, ACROSS

SUBGROUPS IN PATIENTS WITH ACTIVE RA

DESPITE TREATMENT WITH DMARDS

Oral

3L

Tuesday

15.11.2016

16.30

ACR Late-

breaking

Abstract Session

Hall DGiles JT

(USA)

COMPARATIVE CARDIOVASCULAR SAFETY

OF TOCILIZUMAB VS ETANERCEPT IN RA:

RESULTS OF A RANDOMIZED, PARALLEL-

GROUP, MULTICENTER, NONINFERIORITY,

PHASE 4 CLINICAL TRIAL

Oral

3222

Wednesday

16.11.2016

11.15

Small Molecules,

Biologics and

Gene Therapy V:

New Biologics

and Remission

Induction

Hall ETaylor PC

(UK)

EFFICACY AND SAFETY OF MONOTHERAPY

WITH SIRUKUMAB, AN ANTI–IL-6 CYTOKINE

MONOCLONAL ANTIBODY, COMPARED

WITH ADALIMUMAB MONOTHERAPY IN

BIOLOGIC-NAIVE PATIENTS WITH ACTIVE

RA: RESULTS OF A GLOBAL, RANDOMIZED,

DOUBLE-BLIND, PARALLEL-GROUP, PHASE

3 STUDY

Oral

3225

Wednesday

16.11.2016

12.00

Small Molecules,

Biologics and

Gene Therapy V:

New Biologics

and Remission

Induction

Hall EGenovese MC

(USA)

DUAL CYTOKINE INHIBITION WITH ABT-122,

A TNF– AND IL-17–TARGETED DUAL

VARIABLE DOMAIN IMMUNOGLOBULIN

(DVD-IG™): RESULTS FROM A 24-WEEK

OPEN-LABEL EXTENSION STUDY IN

PATIENTS WITH RA





Start

PAGE 8

PSORIATIC ARTHRITIS

Antonis Fanouriakis


Oral

957

Sunday

13.11.2016

14:30

Spondyloarthropathies

and Psoriatic Arthritis -

Clinical Aspects and

Treatment I: Psoriatic

arthritis - Treatment

Salon BOrbai A-M

(USA)

INTERNATIONAL PATIENT AND

PHYSICIAN CONSENSUS ON

PSORIATIC ARTHRITIS OUTCOMES

FOR CLILNICAL TRIALS

Oral

958

Sunday

13.11.2016

14:45




Treatment I: Psoriatic

arthritis - Treatment

Salon BMease P

(USA)

TARGETED DUAL VARIABLE

DOMAIN (DVD)-IGTM, IN PSORIATIC

ARTHRITIS WITH INADEQUATE

RESPONSE TO METHOTREXATE:

RESULTS FROM A PHASE 2 TRIAL

Poster

1708

Monday

14.11.2016

09:00-11:00




Treatment - Poster II:

Psoriatic arthritis

Poster Hall

Hall C

Manasson J

(USA)

CUTANEOUS MICROBIOTA

FEATURES DISTINGUISH

PSORIASIS FROM PSORIATIC

ARTHRITIS

Poster

1725

Monday

14.11.2016

09:00-11:00




Treatment - Poster II:

Psoriatic arthritis

Poster Hall

Hall C

Metyas S

(USA)

COMBINATION THERAPY OF

APREMILAST AND BIOLOGIC AGENT

AS A SAFE OPTION OF PSORIATIC

ARTHRITIS AND PSORIASIS

Poster

2747

Tuesday

15.11.2016

09:00-11:00




Treatment - Poster III

Poster Hall

Hall C

Kalyoncu U

(Turkey)

DAPSA-28 MAY BE USED INSTEAD

OF DAPSA-66/68 IN PSORIATIC

ARTHRITIS

Oral

3095

Tuesday

15.11.2016

16:30




Treatment IV:

Psoriatic arthritis -

Treatment

Salon GCoates L

(UK)

WHAT SHOULD BE THE PRIMARY

TARGET OF “TREAT TO TARGET” IN

PSA?

Oral

3098

Tuesday

15.11.2016

17:15




Treatment IV:

Psoriatic arthritis -

Clinical

Salon GGiles JT

(USA)

THE OCCURENCE OF PERIPHERAL

ARTHRITIS MUTILANS IN PSORIATIC

ARTHRITIS IS ASSOCIATED WITH

CERTAIN MAJOR

HISTOCOMPATIBILITY CLASS I

ALLELLES

Antonis completed his residency in Internal Medicine and Rheumatology in 2014 and is currently working as a consultant

rheumatologist in “Attikon” University Hospital of Athens. He has completed a MSc program in Molecular Medicine and his

thesis on neuropsychiatric systemic lupus erythematosus, both in the University of Crete. His scientific interests focus on

systemic autoimmune diseases, mainly pathogenesis and treatment of SLE.





Start

PAGE 9

Barbara works in the Division of Rheumatology at the University of Genoa and currently is a PhD applicant in Immunology.

Her main interest area focuses on connective tissue diseases.

AXIAL SPONDYLOARTHRITIS

Barbara Ruaro



Poster

675

Sunday

13.11.2016

09:00-11:00

Spondylarthropathies and

Psoriatic Arthritis – Clinical

Aspects and Treatment -

Poster I: Axial and

Peripheral Spondyloarthritis

– Clinical Aspects, Imaging

and Treatment

Poster Hall

Hall C

Dougados M

(France)

ASSOCIATION BETWEEN

STRUCTURAL LESIONS IN THE

SACROILIAC JOINTS AND SPINAL

INFLAMMATORY LESIONS IN

PATIENTS WITH NON-

RADIOGRAPHIC AXIAL

SPONDYLOARTHRITIS

Poster

682

Sunday

13.11.2016

09:00-11:00




Poster I: Axial and



and Treatment

Poster Hall

Hall C

Baraliakos X

(Germany)

WHICH IS THE MOST RELIABLE

IMAGING METHOD FOR DETECTION

OF STRUCTURAL CHANGES IN THE

SACROILIAC JOINTS OF PATIENTS

WITH ANKYLOSING SPONDYLITIS? A

CROSS-SECTIONAL STUDY

COMPARING MRI, CT AND

CONVENTIONAL RADIOGRAPHS

Poster

707

Sunday

13.11.2016

09:00 -11:00




Poster I: Axial and



and Treatment

Poster Hall

Hall C

Atzeni F

(Italy)

ANTI-TNF DRUGS ARE NOT

ASSOCIATED WITH INCREASEAD

RISK OF HZV INFECTIONS IN

PATIENTS WITH

SPONDYLOARTHRITIS (SPA):

RESULTS FROM THE GISEA

REGISTRY

Oral

1045

Sunday

13.11.2016

17:30



Aspects and Treatment II:

Axial Spondyloarthritis –

Treatment

Ballroom BVan der Heijde D

(Netherlands)

2016 UPDATE OF THE ASAS-EULAR

MANAGEMENT RECOMMENDATIONS

FOR AXIAL SPONDYLOARTHRITIS

Oral

1046

Sunday

13.11.2016

17:45



Aspects and Treatment II:


Treatment

Ballroom BRogge L

(France)

ANTI-TNF THERAPY IN AXIAL

SPONDYLOARTHRITIS: PREDICTION

OF THERAPEUTIC RESPONSES

USING IMMUNOLOGICAL

SIGNATURES

Oral

2004

Monday

14.11.2016

15:15

Session:



Aspects and Treatment III:


Clinical

Ballroom AVan Lunteren M

(Netherlands)

IS DISEASE ACTIVITY ASSOCIATED

WITH WORK PRODUCTIVITY LOSS,

PRESENTEEISM AND ABSENTEEISM

IN PATIENTS WITH EARLY AXIAL

SPONDYLOARTHRITIS? RESULTS

FROM THE SPONDYLOARTHRITIS

CAUGHT EARLY (SPACE)-COHORT

Oral,

3158

Wednesday

16.11.2016

09:45

Session:



Aspects and Treatment V:

Imaging of

Spondyloarthritis

Salon BMaksymowych W

(Canada)

WHAT PREDICTS ABSENCE OF

SPINAL DAMAGE IN PATIENTS WITH

SPONDYLOARTHRITIS AFTER

PROLONGED FOLLOW UP?




Start

PAGE 10

Christophe is rheumatologist since 2005 and currently Professor of Rheumatology at Bordeaux Hospital affiliated with

University of Bordeaux. He completed his PhD in immunology in 2009. He has got international experience as research

scholar in Boston University. His main clinical interests are systemic lupus and rheumatoid arthritis. His research focuses on

the involvement of T follicular helper cells in various inflammatory diseases.

SLE & APS

Christophe Richez


Poster

766

Sunday

13.11.2016

09.00

Systemic Lupus

Erythematosus –

Clinical Aspects

and Treatment -

Poster I: Clinical

Trial Design and

Current Therapies

Poster Hall

Hall C

Belmont HM

(USA)

WITHDRAWAL OF MYCOPHENOLATE

MOFETIL AFTER MAINTENANCE

TREATMENT OF SLE NEPHRITIS

ASSOCIATED WITH RENAL RELAPSE

Oral

914

Sunday

13.11.2016

12.15

Plenary Session I:

Discovery 2016Hall D

Hong S.

(USA)

LONGITUDINAL BLOOD

TRANSCRIPTOMICS UNCOVERS IMMUNE

NETWORKS ASSOCIATED WITH

COMPLICATIONS IN LUPUS PREGNANCY

Oral

2013

Monday

14.11.2016

15.45

Systemic Lupus

Erythematosus –

Clinical Aspects

and Treatment III:

Novel and Current

Therapies

Ballroom BFurie R

(USA)

BIIB059, A MONOCLONAL ANTIBODY

TARGETING BDCA2, SHOWS EVIDENCE

OF BIOLOGICAL ACTIVITY AND EARLY

CLINICAL PROOF OF CONCEPT IN

SUBJECTS WITH ACTIVE CUTANEOUS

SLE

Oral

2067

Monday

14.11.2016

17.45

Systemic Lupus

Erythematosus –

Human Etiology

and Pathogenesis I

146 AClancy RM

(USA)

DERMAL FIBROBLASTS FROM PATIENTS

WITH LUPUS NEPHRITIS EXPRESS AN

ANTI-FIBROTIC TRANSCRIPTOME

Poster

2796

Tuesday

15.11.2016

09.00

Systemic Lupus

Erythematosus –

Clinical Aspects

and Treatment -

Poster III:

Biomarkers and

Nephritis

Poster Hall

Hall C

Al-Sheikh H.

(Canada)

LOW VERSUS HIGH DOSE

GLUCOCORTICOSTEROID USED IN

LUPUS NEPHRITIS: IS THERE A

DIFFERENCE

Oral

2984

Tuesday

15.11.2016

11.30

Plenary Session III:

Discovery 2016Hall D

An J

(USA)

NOVEL ANTI-MALARIAL DRUG

DERIVATIVE INHIBITED TYPE I

INTERFERON PRODUCTION AND

AUTOIMMUNE INFLAMMATION THROUGH

INHIBITION OF CGAS-STING PATHWAY IN

TREX1-/- MOUSE

Oral

5L

Tuesday

15.11.2016

16.30

ACR Late-breaking

Abstract SessionHall D

Dooley MA

(USA)

SPEED OF REMISSION WITH THE USE OF

VOCLOSPORIN, MMF AND LOW DOSE

STEROIDS: RESULTS OF A GLOBAL

LUPUS NEPHRITIS STUDY





Start

PAGE 11

OTHER CONNECTIVE TISSUE DISEASES

Including systemic sclerosis, myositis, vasculitis

Mike Becker


Poster

909

Sunday

13.11.2016

09.00

Vasculitis -

Poster I: Large

Vessel

Vasculitis and

Polymyalgia

Rheumatica

Poster Hall

Hall C

Dasgupta B

(UK)

A “YELLOW CARD” REPORTING SYSTEM

FOR SIGHT LOSS IN GIANT CELL

ARTERITIS

Oral

977

Sunday

13.11.2016

15.00

Vasculitis I:

Novel

Approaches to

Therapy

146 ASamson M

(France)

TOCILIZUMAB AS AN ADD-ON THERAPY

TO GLUCOCORTICOIDS DURING THE

FIRST 3 MONTHS OF TREATMENT OF

GIANT CELL ARTERITIS: RESULTS OF A

FRENCH MULTICENTER PROSPECTIVE

OPEN-LABEL STUDY

Oral

978

Sunday

13.11.2016

15.15

Vasculitis I:

Novel

Approaches to

Therapy

146 AMerkel P

(USA)

A RANDOMIZED CLINICAL TRIAL OF

CCX168, AN ORALLY ADMINISTERED

C5AR INHIBITOR FOR TREATMENT OF

PATIENTS WITH ANCA-ASSOCIATED

VASCULITIS

Oral

2019

Monday

14.11.2016

15.45

Systemic

Sclerosis,

Fibrosing

Syndromes, and

Raynaud's –

Clinical Aspects

and

Therapeutics II

145 ALigon C

(USA)

FACES IN MOTION: CLINICAL

SUBTYPING IN SCLERODERMA USING

CHANGES IN FORCED VITAL CAPACITY

Poster

2950

Tuesday

15.11.2016

09.00

Vasculitis -

Poster III: Rarer

Vasculitides

Poster Hall

Hall C

Mekinian A

(France)

COGAN SYNDROME: TREATMENT AND

OUTCOME FROM FRENCH NATIONWIDE

RETROSPECTIVE STUDY AND

LITERATURE REVIEW OF 62 PATIENTS

Oral

3033

Tuesday

15.11.2016

15.30

Sjögren's

Syndrome I:

Clinical Insights

151 ADörner T

(Germany)

SAFETY AND EFFICACY OF SINGLE

DOSE VAY736 (ANTI-BAFF-R MAB) IN

PATIENTS WITH PRIMARY SJÖGREN’S

SYNDROME (PSS)

Oral

3246

Wednesday

16.11.2016

11.15

Systemic

Sclerosis,

Fibrosing

Syndromes, and

Raynaud's –

Clinical Aspects

and

Therapeutics III

146 AKolstad K

(USA)

PREDICTORS OF LONG-TERM

OUTCOMES IN SYSTEMIC SCLEROSIS

ASSOCIATED PULMONARY ARTERIAL

HYPERTENSION FROM THE

PULMONARY HYPERTENSION

ASSESSMENT AND RECOGNITION OF

OUTCOMES IN SCLERODERMA

REGISTRY

After starting out in Haemato-Oncology, Mike was a clinical and research fellow in the Department of Rheumatology and

Clinical Immunology at the Charité Medical Faculty in Berlin, Germany, from 2007-2016. He earned a MSc degree Oxford

University, UK and joined the staff of the Department of Rheumatology at the University Hospital Zürich, Switzerland in 2016.

His main interests are connective tissue diseases, especially systemic sclerosis.





Start

PAGE 12

Joanna graduated at Faculty of Medicine in Medical University of Bydgoszcz and gained her PhD in Rheumatology at the

Medical University of Bydgoszcz in 2014. Joanna is a rheumatologist since 2015. She works as senior assistant at the Jan

Biziel Hospital in Bydgoszcz, Poland. Her main area of research focuses on RA, Sjögren’s syndrome, Hashimoto disease,

effectiveness of radiation synovectomy in rheumatic diseases, SLE and vasculitis.

IMAGING

Joanna Zalewska


Poster

857

Sunday

13.11.2016

09:00-11:00

Vasculitis - Poster I:

Large Vessel Vasculitis

and Polymyalgia

Rheumatica

Poster Hall

Hall C

Schafer V

(Germany)

ULTRASOUND CUT-OFF

VALUES FOR INTIMA- MEDIA

THICKNESS OF TEMPORAL,

FACIAL AND AXILLARY

ARTERIES IN GIANT CELL

ARTERITIS

Poster

150

Sunday

13.11.2016

09:00-11:00

Imaging of Rheumatic

Diseases - Poster I:

Ultrasound and

Emerging Technologies

Poster Hall

Hall C

Huwart A

(France)

ULTRASONOGRAPHY AND

MAGNETIC RESONANCE

IMAGING CHANGES IN

POLYMYALGIA RHEUMATICA

PATIENTS TREATED BY

TOCILIZUMAB

Oral

933

Sunday

13.11.2016

14:30


Diseases I: Advanced

Imaging in RA and

Spondyloarthritides

Salon GGadeholt O

(Germany)

EROSION PATTERNS IN

SEROPOSITIVE AND

SERONEGATIVE RHEUMATOID

ARTHRITIS: A JOINT BY JOINT

APPROACH

Oral

936

Sunday

13.11.2016

15:15


Diseases I: Advanced

Imaging in RA and

Spondyloarthritides

Salon G

Glinatsi D

(Denmark)

RELIABILITY AND

RESPONSIVENESS OF AN

OMERACT TENOSYNOVITIS

MAGNETIC RESONANCE

IMAGING SCORING SYSTEM

FOR THE RHEUMATOID

ARTHRITIS WRIST AND HAND

Oral

1976

Monday

14.11.2016

15:15


Diseases II: Ultrasound

in Rheumatoid Arthritis

Salon GHazes JMW

(Netherlands)

ULTRASOUND INFLAMMATION

IN PATIENTS PRESENTING

WITH ARTHRALGIA IS

ASSOCIATED WITH

DEVELOPING ARTHRITIS

Oral

3197

Wednesday

16.11.2016

11:00


Diseases III: Crystal

Arthritis, Connective

Tissue Diseases and

Vasculitis

Salon B

Chrysidis S

(Denmark)

ULTRASOUND DEFINITIONS

FOR CRANIAL AND LARGE

VESSEL GIANT CELL

ARTERITIS: RESULTS OF A

RELIABILITY EXERCISE ON

IMAGES AND VIDEOS OF THE

OMERACT ULTRASOUND

LARGE VESSEL VASCULITIS

TASK FORCE





Start

PAGE 13

Marie is a clinical fellow in Rheumatology at Bordeaux Hospital, France. She is currently working as a PhD candidate at the

Leiden University Medical Center, Netherlands, on immune infiltrate in bone and soft-tissue tumours.

OSTEOARTHRITIS & OSTEOPOROSIS

Marie Kostine


Poster

315

Sunday

13.11.2016

09.00

Osteoarthritis –

Clinical Aspects

- Poster I

Poster Hall

Hall C

Deseyne N

(France)

HIP INFLAMMATION MRI SCORING

SYSTEM (HIMRISS) TO PREDICT

RESPONSE TO HYALURONIC ACID

(HANOX-M-XL) INJECTION IN HIP

OSTEOARTHRITIS

Oral

1023

Sunday

13.11.2016

16.30

Osteoporosis

and Metabolic

Bone Disease –

Clinical Aspects

and

Pathogenesis

145 ACosman F

(USA)

FRACTURE RISK REDUCTION WITH

ROMOSOZUMAB: RESULTS OF A

PHASE 3 STUDY IN

POSTMENOPAUSAL WOMEN WITH

OSTEOPOROSIS

Oral

1021

Sunday

13.11.2016

17.30

Osteoarthritis –

Clinical Aspects

I: Epidemiology

and Progression

Ballroom CZheng S

(Australia)

MAINTAINING SUFFICIENT SERUM

VITAMIN D LEVELS OVER 2 YEARS

IS ASSOCIATED WITH REDUCED

KNEE STRUCTURAL AND

SYMPTOMATIC CHANGES IN

PATIENTS WITH KNEE

OSTEOARTHRITIS

Oral

1959

Monday

14.11.2016

12.00

Plenary Session

II: Discovery

2016

Hall DSofat N

(UK)

HOW DO BONE MARROW LESIONS

CAUSE OSTEOARTHRITIS PAIN? A

STRUCTURAL AND FUNCTIONAL

TISSUE-BASED STUDY

Poster

2369

Tuesday

15.11.2016

09.00

Osteoarthritis –

Clinical Aspects

- Poster II

Poster Hall

Hall C

Eymard F

(France)

OBESITY AND SEVERITY OF JOINT

SPACE NARROWING ARE

ASSOCIATED WITH

VISCOSUPPLEMENTATION

FAILURE IN PATIENTS WITH KNEE

OSTEOARTHRITIS. POST-HOC

ANALYSIS OF A DOUBLE-BLIND,

CONTROLLED, MULTICENTRE,

RANDOMIZED TRIAL

Oral

3134

Wednesday

16.11.2016

09.45

Osteoarthritis –

Clinical Aspect

II: Treatment

and Imaging

Salon GKingsbury SR

(UK)

HYDROXYCHLOROQUINE IS NOT

EFFECTIVE IN REDUCING

SYMPTOMS OF HAND

OSTEOARTHRITIS: RESULTS

FROM A PLACEBO-CONTROLLED

RANDOMISED TRIAL

Oral

3011

Wednesday

16.11.2016

10.15

Osteoarthritis –

Clinical Aspect

II: Treatment

and Imaging

Salon GSkrepnik N

(USA)

IMPACT OF NOVEL SMARTPHONE

APPLICATION ON PAIN AND

MOBILITY IN OSTEOARTHRITIS

PATIENTS TREATED WITH HYLAN

G-F 20





Start

PAGE 14

Francesco currently works as consultant at the Department of Internal Medicine, ASL 1 Avezzano, L’Aquila, Sulmona, and

senior research fellow at the Rheumatology Unit, University of L’Aquila, Italy. His main interests are Sjögren’s syndrome, B-

cell targeted therapies, salivary gland histopathology, spondyloarthritis and musculoskeletal ultrasonography.

METABOLIC & CRYSTAL ARTHROPATHIES

Francesco Carubbi


Oral

1013

Sunday

13.11.2016

16:45

Muscle Biology,

Myositis and

Myopathies

143 AKwon OC

(Korea)

THE RISK OF COLCHICINE

ASSOCIATED MYOPATHY IN

GOUT: INFLUENCE OF

CONCOMITANT USE OF STATIN

Poster

192

Sunday

13.11.2016

09:00-11:00

Metabolic and

Crystal

Arthropathies -

Poster I: Clinical

Practice

Poster Hall

Hall C

Smith W

(USA)

PHARMACODYNAMIC AND

PHARMACOKINETIC STUDY OF

VERINURAD IN ADULT MALE

SUBJECTS WITH MILD, MODERATE,

AND SEVERE RENAL IMPAIRMENT: A

PHASE 1, OPEN-LABEL STUDY

Poster

155

Sunday

13.11.2016

09:00-11:00

Imaging of

Rheumatic Diseases

- Poster I:

Ultrasound and

Emerging

Technologies

Poster Hall

Hall C

Das S

(India)

EVALUATION OF ULTRASONOGRAPHY

AS MODALITY FOR IDENTIFICATION

OF CALCIUM CRYSTAL DEPOSITS IN

PATIENTS OF PRIMARY

OSTEOARTHRITIS OF KNEE JOINT

Poster

214

Sunday

13.11.2016

09:00-11:00

Metabolic and

Crystal

Arthropathies -

Poster I: Clinical

Practice

Poster Hall

Hall C

Dumusc A

(Switzerland)

ANAKINRA COMPARED TO

PREDNISONE ON THE

TREATMENT OF ACUTE CPPD

CRYSTAL ARTHRITIS, A

RANDOMIZED, CONTROLLED,

DOUBLE-BLIND STUDY

Poster

206

Sunday

13.11.2016

09:00-11:00

Metabolic and

Crystal

Arthropathies -

Poster I: Clinical

Practice

Poster Hall

Hall C

Terkeltaub R

(USA)

RENAL SAFETY OF LESINURAD: A

POOLED ANALYSIS OF PHASE III

AND EXTENSION STUDIES

Poster

233

Sunday

13.11.2016

09:00-11:00

Metabolic and

Crystal

Arthropathies -

Poster I: Clinical

Practice

Poster Hall

Hall C

Ordonez JC

(Spain)

NEW CARDIOVASCULAR RISK

FACTORS SCREENING IN

PATIENTS WITH GOUT

Poster

2276

Tuesday

15.11.2016

09:00-11:00

Metabolic and

Crystal

Arthropathies -

Poster II:

Epidemiology and

Mechanisms of

Disease

Poster Hall

Hall C

Merriman T

(New Zealand)

PLEIOTROPIC EFFECT OF ABCG2

IN GOUT





Start

PAGE 15

PEDIATRIC RHEUMATOLOGY

W. Alberto Sifuentes Giraldo


Poster

388

Sunday

13.11.2016

09.00

Pediatric

Rheumatology –

Clinical and

Therapeutic Aspects -

Poster I: Juvenile

Idiopathic Arthritis,

Uveitis

Poster Hall

Hall C

Brunner HI

(USA)

PHARMACOKINETICS, SAFETY, AND

TOLERABILITY OF TOFACITINIB IN

PEDIATRIC PATIENTS FROM TWO TO

LESS THAN EIGHTEEN YEARS OF AGE

WITH JUVENILE IDIOPATHIC ARTHRITIS

Poster

398

Sunday

13.11.2016

09.00

Pediatric

Rheumatology –

Clinical and


Poster I: Juvenile

Idiopathic Arthritis,

Uveitis

Poster Hall

Hall C

Ruperto N

(Italy)

PREDICTORS OF CLINICAL REMISSION

WITH ETANERCEPT IN PEDIATRIC

PATIENTS WITH EXTENDED

OLIGOARTICULAR, ENTHESITIS-

RELATED ARTHRITIS AND PSORIATIC

ARTHRITIS: FINDINGS FROM THE

CLIPPER STUDY

Oral

950

Sunday

13.11.2016

15.45

Pediatric

Rheumatology –

Clinical and

Therapeutic Aspects

I: Juvenile Arthritis

Ballroom CSimonini G

(Italy)

FLARES AFTER WITHDRAWAL OF

BIOTHERAPIES IN JIA: CLINICAL AND

LABORATORY CORRELATES OF

REMISSION DURATION

Poster

1366

Monday

14.11.2016

09.00

Pediatric

Rheumatology –

Clinical and


Poster II: Myositis,

Systemic Lupus

Erythematosus,

Sjögren's Syndrome

Poster Hall

Hall C

Giancane G

(Italy)

EVIDENCE BASED CRITERIA FOR

CORTICOSTEROID

TAPERING/DISCONTINUATION. AN

ANALYSIS OF THE PEDIATRIC

RHEUMATOLOGY INTERNATIONAL

TRIALS ORGANIZATION (PRINTO) TRIAL

IN NEW ONSET JUVENILE

DERMATOMYOSITIS

Poster

1379

Monday

14.11.2016

09.00

Pediatric

Rheumatology –

Clinical and


Poster II: Myositis,

Systemic Lupus

Erythematosus,

Sjögren's Syndrome

Poster Hall

Hall C

Turnier J

(USA)

EVALUATION OF S100 PROTEINS AS

POTENTIAL BIOMARKERS OF GLOBAL

AND RENAL-SPECIFIC DISEASE

ACTIVITY IN CHILDHOOD-ONSET

SYSTEMIC LUPUS ERYTHEMATOSUS

Oral

3005

Tuesday

15.11.2016

14.30

Pediatric

Rheumatology –

Clinical and

Therapeutic Aspects

II: Juvenile Arthritis

146 AMinoia F

(Italy)

DEVELOPMENT AND INITIAL

VALIDATION OF THE “MH SCORE”, A

NEW DIAGNOSTIC TOOL THAT

DIFFERENTIATES PRIMARY

HEMOPHAGOCYTIC

LYMPHOHISTIOCYTOSIS FROM

MACROPHAGE ACTIVATION SYNDROME

Alberto is a research associate at the Department of Rheumatology of the University Hospital Ramon y Cajal, Madrid, Spain.

His main research interest focuses on pediatric rheumatology, spondyloarthritis and biological therapies.





Start

PAGE 16

RARE AND AUTOINFLAMMATORY DISEASES

Paul Studenic


Oral

3082

Tuesday

15.11.2016

17:45

Miscellaneous

Rheumatic and

Inflammatory

Diseases II

147 AShakoory B

(Iran)

MACROPHAGE ACTIVATION SYNDROME

IS IDENTIFIED BY COAGULOPATHY,

HYPERFERRITINEMIA, FEVER, AND

CYTOPENIA IN HOSPITALIZED PATIENTS,

RESULTING IN POOR OUTCOME

Oral

3081

Tuesday

15.11.2016

17:30

Miscellaneous

Rheumatic and

Inflammatory

Diseases II

147 ABrito-Zeron P

(Spain)

PROGNOSTIC FACTORS OF DEATH IN A

COHORT OF 116 ADULTS WITH

HEMOPHAGOCYTIC SYNDROME: IMPACT

OF UNDERLYING DISEASE AND

LABORATORY PARAMETERS

Poster

260

Sunday

13.11.2016

09:00-

11:00

Miscellaneous

Rheumatic and

Inflammatory

Diseases -

Poster I

Poster Hall

Hall C

Ungprasert P

(USA)

RISK OF CARDIOVASCULAR DISEASE

AMONG PATIENTS WITH

SARCOIDOSIS: A POPULATION-

BASED RETROSPECTIVE COHORT

STUDY

Poster

236

Sunday

13.11.2016

09:00-

11:00

Miscellaneous

Rheumatic and

Inflammatory

Diseases -

Poster I

Poster Hall

Hall C

Lim SY

(USA)

INTRATHORACIC MANIFESTATIONS

OF IGG4-RELATED DISEASE:

FINDINGS IN A COHORT STUDY

FROM NORTH AMERICA

Poster

244

Sunday

13.11.2016

09:00-

11:00

Miscellaneous

Rheumatic and

Inflammatory

Diseases -

Poster I

Poster Hall

Hall C

Wang Y

(China)

LEFLUNOMIDE AND

GLUCOCORTICOIDS COMBINATION

THERAPY FOR THE INDUCTION AND

MAINTENANCE OF REMISSION IN

PATIENTS WITH IGG4-RELATED

DISEASE

Poster

255

Sunday

13.11.2016

09:00-

11:00

Miscellaneous

Rheumatic and

Inflammatory

Diseases -

Poster I

Poster Hall

Hall C

Hoffman H

(USA)

SAFETY AND EFFICACY OF LONG-

TERM CANAKINUMAB THERAPY IN

PATIENTS WITH CAPS: FINAL

RESULTS FROM BETA-CONFIDENT

REGISTRY

Paul is a medical resident and clinical research fellow at the division of rheumatology of the Medical University Vienna in

Austria. His main interests are outcomes assessment in RA and PsoA, patient reported outcomes, predictors of disease

activity, biomarkers and elderly patients.



Ursprungsform

im Menü über:


YOUR OPINION IS IMPORTANT!

If you are one of the mentees that will participate in the meetings give us your feedback after the

event and it will be included in next Newsletter issue!

THE MENTOR MENTEE MEETINGS

PAGE 17

THE MENTOR MENTEE MEETINGS AT ACR 2016

EMEUNET offers you an unique opportunity to discuss about possible career options, your

research and your involvement in EULAR with leaders in the field in an informal way. Sign up

for the mentor-mentee meetings at ACR 2016, Washington. As you all know, one of the

missions of EMEUNET is increasing the mentor-mentee interaction. Previous mentor-mentees

meetings at EULAR and ACR have been very interactive and were scored very satisfactory by

mentees. The mentor-mentee meetings will last approximately 1 hour and the number of mentees

will be limited to 4-6 for each group to enhance interaction. Here are the 2 professors that will

guide as mentors:

PROFESSOR: Ronald F van Vollenhoven (Amsterdam Rheumatology Center, Amsterdam, the

Netherlands)

AREA: Development and systematic evaluation of biological and immunomodulatory treatments

for the rheumatic diseases, biologic treatment registries.

PROFESSOR: Margreet Kloppenburg (Leiden University Medical Center, Leiden, the Netherlands)

AREA: Outcomes assessment and radiographic and MRI scoring methods in osteoarthritis.


Ursprungsform

im Menü über:


NETWORKING EVENT AT ACR 2016

PAGE 18

EMEUNET MEET UP ACR WASHINGTON 2016

Sunday 13th of November 6.00pm

EMEUNET activities won t stop while we are on the other side of the ocean for the ACR: join us for

sightseeing, drinks, and food on Sunday the 13th!

We will meet at the registration area of the conference centre at 6.00pm (after the last session).

We will have a walk in the monumental city of Washington, followed by drinks, food, and fun at the

Penn Social Bar, 801 E St NW, Washington, DC 20004, http://www.pennsocialdc.com/ where we

can chat, drink, eat and play some games (e.g. football, ping pong and so on). Should you be late

and miss the tour you can join us directly at the bar after 7pm.

This is a free event (drinks and food at your expenses) but please register your interest at the link

below so that we have an idea of how many people will be at the bar.

Please visit https://emeunet.eventsmart.com/, it will just take you one minute but we will give us

the possibility to know the numbers and (most importantly) contact you to confirm the meeting

point at the ACR conference centre.

Looking forward to meeting you in Washington.

Save the date: Sunday 13th of November 6.00pm

http://www.pennsocialdc.com/

https://emeunet.eventsmart.com/


Ursprungsform

im Menü über:


UPCOMING EDUCATIONAL EVENTS AT A GLANCE

PAGE 19

EDUCATIONAL EVENTS

NOVEMBER 2016

Basic Musculoskeletal Ultrasound (MSUS) Course

o When and Where: 4-6 November 2016, Manama, Bahrain

o Website: http://eular.org/www.bahrain-mskultrasound.com

IOF Regionals 6th Asia-Pacific Osteoporosis Meeting - International

Osteoporosis Foundation

o When and Where: 4-6 November 2016, Singapore

o Website: http://www.suntecsingapore.com/#axzz3q3vyi6z9

American College of Rheumatology (ACR) Annual Meeting

o When and Where: 11-16 November, Washington DC, USA

o Website: http://acrannualmeeting.org/


Ursprungsform

im Menü über:


MORE ON EDUCATION

PAGE 20

THE EMEUNET CALENDAR

We have recently set up a new calendar of events and deadlines that can be found on the

EMEUNET website http://emeunet.eular.org/calendar.cfm

This calendar offers the great opportunity to be synchronized with your own agenda, so that you

will never miss a deadline!

You can use applications such as outlook, using the following ICAL links:

For deadlines: ICS file deadlines

For events: ICS file events

Following the links, you will download a .ics file, if you have outlook installed the calendar should

be automatically added to your agenda when opening the file.

If you have an android phone, the calendar will be automatically available on your phone.

If you have an iPhone, you can easily set it to automatically synchronize with a google account, by

following the instructions at this link

http://www.digitaltrends.com/mobile/sync-multiple-google-calendars-on-iphone-or-ipad

We hope you will find this service useful and we welcome your feedback, should anything go

wrong with the synchronization or should you have any suggestions.

Your EMEUNET Education and Social Media Subgroups

Young investigators of EMEUNET are from now on an integral part of all task forces and

committees working on new EULAR recommendations. This is a wonderful chance for

EMEUNET to increase its visibility and for you to accelerate your academic career.

Last call came from the EULAR study group for the new EULAR recommendations for the

management of foot and ankle conditions in people with rheumatoid arthritis.

Take a look at emails from EMEUNET and find the opportunity most suitable for you!

JOIN THE TASK FORCES AND COMMITTEES

http://emeunet.eular.org/calendar.cfm

http://tinyurl.com/z5sy9lb

http://tinyurl.com/hbfo4mx

http://www.digitaltrends.com/mobile/sync-multiple-google-calendars-on-iphone-or-ipad




Start

WORLD ARTHRITIS DAY

PAGE 21

EMEUNET @ EULAR Brussels conference on

reducing burden in workplace for people with RMDs

The 12th of October 2016 marked the World Arthritis Day. In light of this and as in previous years,

EULAR organised a conference in Brussels to raise awareness on Rheumatic and Musculoskeletal

Diseases (RMDs), this year with a focus on reducing burden in workplaces for people with RMDs. On

this important day for all people with RMDs, their caregivers and people who work towards improving

the quality of life of patients, discussions focused on identifying and discussing relevant topics

concerning potential issues and barriers in the current working environments across Europe. This

meeting gathered patient representatives, the EULAR steering committee (EULAR President Prof.

Gerd Burmester, Past-President Prof Maurizio Cutolo, President Elect Prof. Hans Bijlsma), the Vice

president of EULAR for PARE Marios Kouloumas as well as representatives from the European

Parliament, the European Commission and national rheumatology societies from EULAR countries.

The meeting included introductory lectures followed by three group workshops, a reporting back of the

results to all participants and a plenary discussion on the possible impact of the workshop results on

EU policy makers to improve conditions at European level.

Three main topics were addressed in these workshops:

o “How to facilitate the retention of people with RMDs in work and return to work after sick leave?”.

Main points stemming out of this included the need for more flexibility in working hours of physicians

and good self-management skills for patients. The discussions highlighted the challenges of dealing

with an invisible but painful illness and non-affected people’s understanding of this

o “Primary, secondary and tertiary prevention of RMDs in work place - legislation and policy

initiatives”. At EU institution level, legislation should be adapted to the needs arising from changes in

organisations, guidelines for implementation should be proposed and the definition of disability

should be altered. Single-member states could especially deduct the taxes for healthy work

environment.

o “Dealing with RMDs in the workplace - access to occupational health professionals”. The most

essential points raised in this discussion were the need for a more cross-sectional cooperation

across EU-institutions and funding for randomized controlled trials for occupational rehabilitation.

Furthermore, the lack of information concerning the contribution of occupational health to patient

care was discussed, highlighting the need of incorporating such interventions to patient care.

We attended this conference on behalf of EMEUNET to bring in potential input from experiences and

viewpoints of young rheumatologists. The conference was covered via live streaming and twitter

(official hashtag: #EularBrussels16), so that everyone from home could follow the developments over

the day. EMEUNET also contributed to the ARD twitter platform, as well as EMEUNET Facebook,

spreading the news further and ensuring high engagement across these platforms.

Alessia Alunno, Elena Nikiphorou and Paul Studenic

acr do not miss - emeunet 2016 dnm issue_final.pdfacr do not miss acr 2016 washington oral...

Documents